A pilot randomized trial of pentoxifylline for the reduction of periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention

作者：Aslanabadi Naser; Shirzadi Hamid Reza; Asghari Soufi Hossein; Dousti Samaneh; Ghaffari Samad; Sohrabi Bahram; Mashayekhi Simin Ozar; Hamishehkar Hadi; Entezari Maleki Taher^*

来源：European Journal of Clinical Pharmacology, 2015, 71(2): 143-149.

DOI：10.1007/s00228-014-1782-y

• Pentoxifylline
• Periprocedural myocardial injury
• PCI
• Cardiac biomarkers
• Creatine kinase-MB
• Troponin-I

Periprocedural myocardial injury (PMI) following percutaneous coronary intervention (PCI) has received great attention due to its significant association with mortality and morbidity. Accordingly, cardioprotection during PCI is one of the important therapeutic concerns. Regarding the potential cardiovascular benefits of pentoxifylline this study was performed to evaluate whether the pretreatment pentoxifylline could reduce PMI in patients who are undergoing elective PCI.
A randomized clinical trial on 85 patients undergoing elective PCI was performed. The intervention group (n = 41) received 1200 mg pentoxifylline in divided doses plus the standard treatment before PCI, while the control group (n = 44) received the standard treatment. For assessing myocardial damage during PCI, the levels of CK-MB and troponin-I were measured at baseline, 8, and 24 h after the procedure. Then, patients were followed up for a 1-month period regarding the major adverse cardiac effect.
Comparing with the control group, no significant change of CK-MB at 8 (p = 0.315) and 24 h (p = 0.896) after PCI was documented in pentoxifylline group. Similarly, no significant change was found in troponin-I at 8 (p = 0.141) and 24 h (p = 0.256) after PCI.
This study could not support the pretreatment with pentoxifylline in the prevention of PMI in patients undergoing elective PCI. However, the trend was toward the potential benefit of pentoxifylline.

• 出版日期2015-2